Scribe Therapeutics snags $100M for engineered CRISPR tech, pipeline
Scribe Therapeutics is adding another $100 million to its coffers six months after unveiling a $20 million series A and a partnership with Biogen to work on gene editing treatments for amyotrophic lateral sclerosis (ALS). The new funds will support the development of the company’s gene editing and delivery technologies and propel a pipeline of treatments for neurodegeneration and other diseases.
That initial round was about laying the groundwork for a company that aims to overcome the obstacles in CRISPR, Scribe CEO Benjamin Oakes, Ph.D., who founded the company alongside Nobel Prize winner Jennifer Doudna, Ph.D., Brett Staahl, Ph.D., and David Savage, Ph.D.
“Our last round was very much ‘just do it,’ building our core … This round is more about building the entire organization,” Oakes said.
